welcome to oneEDSvoice
- a positively charged Ehlers Danlos Syndrome community.- join today!
- login
Acer jumps on 7-year-old data
Acer Therapeutics Inc. had a welcoming first week on the Nasdaq stock exchange, seeing shares sruge more 10% Monday after verifying positive clinical results published almost seven years ago from a study of celiprolol, the active ingredient in its lead drug candidate.
The study tested celiprolol against placebo in patients with vascular Ehlers-Danlos Syndrome (vEDS), a rare, life-threatening disorder that causes arteries and organs to easily rupture. After receiving treatment for about four years on average, 20% of the participants in the investigational arm experienced arterial events versus 50% of those in the control arm.

expertly curated content related to this topic
-
Sunshine and SpoonsI'm Hannah, a mom of four who loves Jesu...
-
Three Cases Exhibiting the Ehlers-Danlos SyndromeMrs. W., aged 51 (mother), Miss W., aged...
-
Educational EDS one-pager from Chiari & Syringomyelia FoundationEhlers-Danlos Syndrome (EDS) is a heredi...
-
‘Most Neglected Disorder in Modern Medicine’ Receives Major Classification UpdateThe American Journal of Medical Genetics...